Skip to main content
. 2019 Nov 28;37(2):267–276. doi: 10.1111/dme.14178

Figure 2.

Figure 2

Percentage of participants reaching HbA1c < 53 mmol/mol (7.0%) at end of trial in the (a) DUAL V and (b) DUAL VII trials. Data are percentages based on the full analysis set using either observed data with last observation carried forward imputed data for DUAL V or observed data with no imputation for DUAL VII. IAsp, insulin aspart; IDegLira, insulin degludec/liraglutide; IGlar U100, insulin glargine 100 units/ml.